MedPath

Study to Evaluate Satisfaction After Treatment With Restylane

Not Applicable
Completed
Conditions
Cheek Augmentation
Interventions
Device: Restylane Volyme
Device: Restylane Lyft Lidocaine
Registration Number
NCT04638816
Lead Sponsor
Galderma R&D
Brief Summary

Open-label, phase IV, post-marketing study to evaluate aesthetic improvement and satisfaction after treatment with Restylane

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • Signed and dated informed consent to participate in the study
  • Adult women who intend to undergo cheek augmentation
Exclusion Criteria
  • Subjects presenting with known allergy to HA (hyaluronic acid) filler or amide local anesthetics
  • Subjects with a previous implant other than HA in or near the intended treatment site
  • Participation in any other clinical study within three (3) months before treatment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Restylane VolymeRestylane VolymeHyaluronic Acid
Restylane Lyft LidocaineRestylane Lyft LidocaineHyaluronic Acid
Primary Outcome Measures
NameTimeMethod
Assess Treatment With Restylane Volyme and Restylane Lyft Lidocaine Using GAIS4 weeks after last treatment, up to 6 weeks

The 7-grade Global Aesthetic Improvement Scale (GAIS) assess the appearance of the treatment area (cheeks) compared to pre-treatment. The rating is very much improved, much improved, improved, no change, worse, much worse, or very much worse.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Galderma Study Site

🇨🇦

Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath